Spots Global Cancer Trial Database for Clinical Trial of PXD101 in Patients With Advanced Multiple Myeloma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Clinical Trial of PXD101 in Patients With Advanced Multiple Myeloma
Official Title: A Phase II Clinical Trial of PXD101 in Patients With Advanced Multiple Myeloma
Study ID: NCT00131261
Conditions
Study Description
Brief Summary: The purpose of this open-label, non-randomized trial is to assess the safety and effectiveness of PXD101, both alone and in combination with dexamethasone, in patients with advanced multiple myeloma. PXD101 is a new, potent histone deacetylase (HDAC) inhibitor. Various members of this class of drugs have shown activity in preclinical studies and in initial clinical trials of multiple myeloma and lymphoma. Furthermore, HDAC inhibitors, including PXD101, have been shown to sensitize myeloma cells to the killing effect of other chemotherapeutic agents, including dexamethasone, a well-established agent in relapsing myeloma.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
James Berenson, MD, Inc, West Hollywood, California, United States
H. Lee Moffitt Cancer Center, Tampa, Florida, United States
Northwestern University, Chicago, Illinois, United States
Research Facility, New York, New York, United States
Rigshospitalet, Copenhagen, , Denmark
Research Facility, Bergen, , Norway
Research Facility, Oslo, , Norway
Research Facility, Trondheim, , Norway
Christie Hospital NHS Trust, Manchester, , United Kingdom
The Royal Marsden NHS Trust, Surrey, , United Kingdom
Contact Details
Name: enquiries@topotarget.com
Affiliation: Valerio Therapeutics
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
